Vasa

Instructions to Authors



Vasa – European Journal of Vascular Medicine publishes papers from clinical and experimental angiology; all papers must not have been published elsewhere nor be under consideration at another publication. All original papers, reviews, case reports and letters to the Editor must be in English. Acceptance of the paper by editors automatically transfers the copyright to the Publishers in accordance with existing copyright laws.

Copyright

The author confirms and guarantees on behalf of him-/herself and any coauthors that he or she holds all copyright in and titles to the submitted contribution, including any figures, photographs, line drawings, plants, maps, sketches, and tables, and that the article and its contents do not infringe in any way on the rights of third parties. Upon acceptance of the article for publication, the author agrees to transfer to the publisher the exclusive right to reproduce and distribute the article and its contents, both physically and in non-physical, electronic, or other form, in the journal to which it has been submitted and in other independent publications, with no limitations on the number of copies or on the form or the extent of distribution. These rights are transferred for the duration of copyright as defined by Swiss law. Furthermore, the author transfers to the publisher the fol-lowing exclusive rights to the article and its contents:

- · The rights to produce advance copies, reprints or offprints of the article, in full or in part, to undertake or allow translations into other languages, to distribute other forms or modified versions of the article, and to produce and distribute summaries or abstracts.
- · The rights to microfilm and microfiche editions or similar, to the use of the article and its contents in videotext, teletext, and similar systems, to recordings or reproduction on other media, digital or analogue, including electronic, magnetic, and optical media, and in multimedia form, as well as for public broadcasting in radio, television, or other forms of braodcast. c) The rights to store the article and its contents in machine-readable or electronic form on all media (such as computer disks, compact disks, magnetic tape), to store the article and its contents in online databases belonging to the publisher or to third parties for viewing or for downloading by third parties, and to present or reproduce the article or its contents on visual display screens, monitors, and similar devices, either directly or via data transmission.
- The rights to reproduce and distribute the article and its contents by all other means, including photomechanical and similar processes (such as photocopying or facsimile), and as part of so-called document delivery services.
- The right to transfer any or all of the rights mentioned in this agreement as well as the rights retained by the Verwer-tungsgesellschaft «WORT» including the corresponding royalty rights to third parties within or outside Switzerland.

Manuscript Submission

Authors should submit the manuscript in electronic form to http://www.editorialmanager.com/vasa. The online manuscript submission and review system for the journal offers easy and straightforward log-in and submission procedures. This system supports a wide range of submission file formats: for manuscripts - Word, WordPerfect, RTF, TXT and LaTex; for figures - TIFF, GIF, JPEG, EPS, PPT, and Postscript. Each page of the manuscript should contain the page number in the upper right-hand corner. Please do not send any hard copies of the manuscript.

Preparation of the manuscript

Ethics of investigation on human subjects: In manuscripts describing research on humans, the authors should include a statement that the protocol was reviewed and approved by the appropriate Ethical Committee.

Editorial Manager will create a title page itself, so it's not needed to add a title page.

The maximum lenght per article in the different categories is defined as follows:

Editorial

max. 1'500 words and 15 references

Review

max. 7 000 words and 75 references

Original communications

max, 4000 words and 30 references

Case report

max. 2000 words and 20 references

Letter to the Editor

max. 600 words and 5 references

Abstract

The abstract should contain a maximum of 300 words, for original contributions structured like the paper itself (Background, Patients and methods, Results, Conclusions).

Key message

Case reports include a core message of max. 50 words instead of an abstract. Please also supply a maximum of six keywords and a running title in English for indexing purposes.

Main body

The paper itself should be structured according to international standards and contain the following sections: Introduction, Aims, Material and Methods, Results, Discussion, Summary, if necessary with subheadings.

Frequently used abbreviations should be written out upon initial employment, followed by the proper abbreviation in parentheses.

Word count

The total word count must be indicated on the main body document. Tables should be numbered sequentially in Roman numerals. Figures should be submitted in reproducible form (unscreened originals, blackand- white glossies, laser printouts of graphs, slides) and numbered sequentially in Arabic numbers. The figure legends should be printed on a separate sheet. Only a total of 6 figures and tables are allowed.

Electronic supplementary material (ESM)

may be submitted. This material (further tables, figures, audio and video files, etc.) will be published online only and with free access.

References

The reference list should be submitted as an own document and should conform to the Vancouver Style (see examples). References are numbered consecutively in the order in which they are first mentioned. Each reference is listed once only.

Only up to three authors of each reference can be listed, the rest must be abbreviated by "et al.". References in the text should be put in square brackets, except when authors are mentioned for stylistic reasons. The journal names should be abbreviated in accordance with the List of Journals in the Index Medicus.

Examples

- Murphy MP, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg 2011;53:1565-74.
- · Wester T, Jorgensen JJ, Stranden E, Sandbaek G, Tjonnfjord G, Bay D, et al. Treatment with autologous bone marrow mononuclear cells in patients with critical lower limb ischaemia. A pilot study. Scand J Surg 2008;97:56-62.

- Benoit E, O'Donnell TF, Iafrati MD, Asher E, Bandyk DF, Hallett JW, et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 2011:9:165.
- · Barc P, Skora J, Pupka A, Turkiewicz D, Dorobisz AT, Gargarek J, et al. Bone-marrow cells in therapy of critical limb ischemia of lower extremities - our own experience. Acta Angiologica 2006;12:155-66.

The correspondence address must be set directly into the system (Editorial Manager) and encompass academic title and complete address, including international country abbreviation and e-mail address.

The correction proof shall be sent to the corresponding author. Changes of content or style should be made only in exceptional cases. Correction costs exceeding 5 % of the typesetting costs shall be invoiced to the author(s). The Hogrefe Group will send the corresponding author of each accepted paper free of charge an e-offprint (PDF) of the published version when it is first released online. This e-offprint is provided for the author's personal use, including for sharing with coauthors.